109 related articles for article (PubMed ID: 11683426)
1. Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: a randomized placebo-controlled study.
Katase K; Kato T; Hirai Y; Hasumi K; Chen JT
Calcif Tissue Int; 2001 Aug; 69(2):73-7. PubMed ID: 11683426
[TBL] [Abstract][Full Text] [Related]
2. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
Nozaki M; Hashimoto K; Inoue Y; Ogata R; Okuma A; Nakano H
Int J Gynaecol Obstet; 1998 Jul; 62(1):69-75. PubMed ID: 9722129
[TBL] [Abstract][Full Text] [Related]
3. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
[TBL] [Abstract][Full Text] [Related]
4. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.
Valente M; Bufalino L; Castiglione GN; D'Angelo R; Mancuso A; Galoppi P; Zichella L
Calcif Tissue Int; 1994 May; 54(5):377-80. PubMed ID: 8062153
[TBL] [Abstract][Full Text] [Related]
5. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
6. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
Alexandersen P; Toussaint A; Christiansen C; Devogelaer JP; Roux C; Fechtenbaum J; Gennari C; Reginster JY;
JAMA; 2001 Mar; 285(11):1482-8. PubMed ID: 11255425
[TBL] [Abstract][Full Text] [Related]
7. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists.
Gambacciani M; Cappagli B; Piaggesi L; Ciaponi M; Genazzani AR
Calcif Tissue Int; 1997; 61 Suppl 1():S15-8. PubMed ID: 9263611
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of ipriflavone in postmenopausal women with osteopenia or osteoporosis: A systematic review and meta-analysis.
Hu Q; Long C; Wu D; You X; Ran L; Xu J; O Klineberg E; Huang S; Chen J; Ning N
Pharmacol Res; 2020 Sep; 159():104860. PubMed ID: 32407952
[TBL] [Abstract][Full Text] [Related]
9. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
10. Soymilk or progesterone for prevention of bone loss--a 2 year randomized, placebo-controlled trial.
Lydeking-Olsen E; Beck-Jensen JE; Setchell KD; Holm-Jensen T
Eur J Nutr; 2004 Aug; 43(4):246-57. PubMed ID: 15309425
[TBL] [Abstract][Full Text] [Related]
11. Soy isoflavones attenuate bone loss in early postmenopausal Chinese women : a single-blind randomized, placebo-controlled trial.
Ye YB; Tang XY; Verbruggen MA; Su YX
Eur J Nutr; 2006 Sep; 45(6):327-34. PubMed ID: 16763748
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
Kovács AB
Agents Actions; 1994 Mar; 41(1-2):86-7. PubMed ID: 8079827
[TBL] [Abstract][Full Text] [Related]
13. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
[TBL] [Abstract][Full Text] [Related]
14. Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
Melis GB; Paoletti AM; Bartolini R; Tosti Balducci M; Massi GB; Bruni V; Becorpi A; Ottanelli S; Fioretti P; Gambacciani M
Bone Miner; 1992 Oct; 19 Suppl 1():S49-56. PubMed ID: 1422321
[TBL] [Abstract][Full Text] [Related]
15. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
16. Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass.
Ohta H; Komukai S; Makita K; Masuzawa T; Nozawa S
Horm Res; 1999; 51(4):178-83. PubMed ID: 10474019
[TBL] [Abstract][Full Text] [Related]
17. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.
Agnusdei D; Gennari C; Bufalino L
Osteoporos Int; 1995; 5(6):462-6. PubMed ID: 8695969
[TBL] [Abstract][Full Text] [Related]
18. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
19. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
Adami S; Bufalino L; Cervetti R; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Serni U; Vecchiet L; Passeri M
Osteoporos Int; 1997; 7(2):119-25. PubMed ID: 9166391
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ipriflavone in established osteoporosis and long-term safety.
Agnusdei D; Bufalino L
Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]